Global Hypercalcemia Treatment Market, 2018-2026: Market is Projected to Reach Over $23 Billion - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Global Hypercalcemia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering.
The global hypercalcemia treatment market is projected to reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026.
Hypercalcemia is a metabolic disorder caused by elevated levels of calcium, with serum calcium levels above 2.6 mmol/L. Hypercalcemia is generally a result of overactive parathyroid glands and may occur in cancer patients, majorly in lung and breast cancer patients. Some other factors contributing development of disorder includes hereditary factors, severe dehydration, medications, and supplements. Patients are prescribed calcium regulating therapeutics.
Based on the drug class, the global hypercalcemia treatment market is segmented into bisphosphonates, calcitonin, glucocorticoids, calcimimetic agents, and denusomab. Bisphosphonates is further sub-segmented into clodronate, etidronate, ibandronate, pamidronate, and zoledronic acid.
In 2017, bisphosphonates segment dominated the global hypercalcemia treatment market due to increased preference for treatment of the disease. Other drug classes including glucocorticoids and calcimimetic agents are expected to experience a steady growth during the forecast period. As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market.
Key players in the market include Amgen, Inc., Bayer Pharma AG, Mylan N.V., Pfizer Inc., Cipla, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and Dr. Reddy’s Laboratories Ltd.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Hypercalcemia Treatment Market: Dynamics & Future Outlook
Chapter 4 Global Hypercalcemia Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
Chapter 5 Global Hypercalcemia Treatment Market, by Geography, 2016-2026 (US$ Mn)
Chapter 6 Company ProfilesAmgen, Inc. Bayer Pharma AG Cipla, Inc. Dr. Reddy’s Laboratories, Ltd. Mylan N.V. Novartis AG Pfizer, Inc. Sun Pharmaceutical Industries, Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/jvzktx/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180613005463/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/13/2018 05:19 AM/DISC: 06/13/2018 05:19 AM